• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cost-effectiveness analysis of the Spanish renal replacement therapy program.西班牙肾脏替代治疗方案的成本效益分析。
Perit Dial Int. 2012 Mar-Apr;32(2):192-9. doi: 10.3747/pdi.2011.00037. Epub 2011 Sep 30.
2
Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China.中国南方广州市肾脏替代治疗策略的成本效益分析
BMJ Open. 2021 Feb 5;11(2):e039653. doi: 10.1136/bmjopen-2020-039653.
3
Cost-effectiveness analysis of timely dialysis referral after renal transplant failure in Spain.西班牙肾移植失败后及时透析转介的成本效益分析。
BMC Health Serv Res. 2012 Aug 16;12:257. doi: 10.1186/1472-6963-12-257.
4
Cost analysis of the Spanish renal replacement therapy programme.西班牙肾脏替代治疗项目的成本分析。
Nephrol Dial Transplant. 2011 Nov;26(11):3709-14. doi: 10.1093/ndt/gfr088. Epub 2011 Mar 21.
5
Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective?伊朗终末期肾病患者中腹膜透析与血液透析的比较:哪种更具成本效益?
BMC Nephrol. 2024 Mar 6;25(1):85. doi: 10.1186/s12882-024-03530-0.
6
Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.腹膜透析优先政策下终末期肾病患者一线透析方式的终身成本效益分析
BMC Nephrol. 2020 Feb 4;21(1):42. doi: 10.1186/s12882-020-1708-0.
7
Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.新加坡终末期肾病患者血液透析和腹膜透析的成本效益
Nephrology (Carlton). 2016 Aug;21(8):669-77. doi: 10.1111/nep.12668.
8
Filtering for the best policy: An economic evaluation of policy options for kidney replacement coverage in the Philippines.最优政策筛选:菲律宾肾脏替代治疗覆盖政策选择的经济评估。
Nephrology (Carlton). 2021 Feb;26(2):170-177. doi: 10.1111/nep.13830. Epub 2021 Jan 13.
9
Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.终末期肾病姑息治疗与腹膜透析和血液透析的经济学评估:泰国医保覆盖决策的证据
Value Health. 2007 Jan-Feb;10(1):61-72. doi: 10.1111/j.1524-4733.2006.00145.x.
10
Cost-effectiveness analysis of renal replacement therapy in Austria.奥地利肾脏替代治疗的成本效益分析。
Nephrol Dial Transplant. 2011 Sep;26(9):2988-95. doi: 10.1093/ndt/gfq780. Epub 2011 Feb 10.

引用本文的文献

1
Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure.利用经济评估为肾衰竭治疗可及性相关政策提供信息的指南。
Nat Rev Nephrol. 2025 Sep 11. doi: 10.1038/s41581-025-01000-w.
2
A systematic review and quality assessment of economic evaluations of kidney replacement therapies in end-stage kidney disease.一项关于终末期肾病肾脏替代治疗的经济评价的系统回顾和质量评估。
Sci Rep. 2024 Oct 3;14(1):23018. doi: 10.1038/s41598-024-73735-8.
3
Urgent Implantation of Peritoneal Dialysis Catheter in Chronic Kidney Disease and Acute Kidney Injury-A Review.慢性肾脏病和急性肾损伤中腹膜透析导管的紧急植入——综述
J Clin Med. 2023 Aug 2;12(15):5079. doi: 10.3390/jcm12155079.
4
A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway.一项关于肾脏替代疗法的成本效益的系统评价,以及对终末期肾病治疗途径中决策的影响。
Eur J Health Econ. 2023 Apr;24(3):377-392. doi: 10.1007/s10198-022-01478-2. Epub 2022 Jun 18.
5
Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China.中国南方广州市肾脏替代治疗策略的成本效益分析
BMJ Open. 2021 Feb 5;11(2):e039653. doi: 10.1136/bmjopen-2020-039653.
6
Perceived Stress in Relation to Quality of Life and Resilience in Patients with Advanced Chronic Kidney Disease Undergoing Hemodialysis.接受血液透析的晚期慢性肾脏病患者的感知压力与生活质量和韧性的关系。
Int J Environ Res Public Health. 2021 Jan 11;18(2):536. doi: 10.3390/ijerph18020536.
7
The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations.肾脏替代治疗模式的成本效益:全经济评估的系统评价。
Appl Health Econ Health Policy. 2021 Mar;19(2):163-180. doi: 10.1007/s40258-020-00614-4. Epub 2020 Oct 13.
8
Cost of Hemodialysis Treatment and Associated Factors Among End-Stage Renal Disease Patients at the Tertiary Hospitals of Addis Ababa City and Amhara Region, Ethiopia.埃塞俄比亚亚的斯亚贝巴市和阿姆哈拉地区三级医院终末期肾病患者的血液透析治疗费用及相关因素
Clinicoecon Outcomes Res. 2020 Jul 27;12:399-409. doi: 10.2147/CEOR.S256947. eCollection 2020.
9
Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.腹膜透析优先政策下终末期肾病患者一线透析方式的终身成本效益分析
BMC Nephrol. 2020 Feb 4;21(1):42. doi: 10.1186/s12882-020-1708-0.
10
Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.马来西亚卫生部透析中心终末期肾病治疗的成本效用分析:血液透析与持续不卧床腹膜透析比较。
PLoS One. 2019 Oct 23;14(10):e0218422. doi: 10.1371/journal.pone.0218422. eCollection 2019.

本文引用的文献

1
Cost analysis of the Spanish renal replacement therapy programme.西班牙肾脏替代治疗项目的成本分析。
Nephrol Dial Transplant. 2011 Nov;26(11):3709-14. doi: 10.1093/ndt/gfr088. Epub 2011 Mar 21.
2
[SEN-SEMFYC consensus document on chronic kidney disease].[慢性肾脏病的SEN-SEMFYC共识文件]
Nefrologia. 2008;28(3):273-82.
3
Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis.接受肾脏替代治疗患者基于偏好的生活质量:一项系统评价与荟萃分析
Value Health. 2008 Jul-Aug;11(4):733-41. doi: 10.1111/j.1524-4733.2007.00308.x. Epub 2008 Jan 8.
4
Cost/Utility study of peritoneal dialysis and hemodialysis in Chile.智利腹膜透析和血液透析的成本/效用研究。
Perit Dial Int. 2007 May-Jun;27(3):359-63.
5
Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease.持续性非卧床腹膜透析与自动化腹膜透析治疗终末期肾病的比较
Cochrane Database Syst Rev. 2007 Apr 18;2007(2):CD006515. doi: 10.1002/14651858.CD006515.
6
[Estimating utility values for health status using the Spanish version of the SF-36. Validity of the SF-6D index vs EQ-5D].[使用西班牙语版SF-36评估健康状况的效用值。SF-6D指数与EQ-5D的有效性]
Med Clin (Barc). 2007 Apr 14;128(14):536-7. doi: 10.1157/13101163.
7
[Guidelines of the Spanish Society of Nephrology. Clinical practice guidelines for peritoneal dialysis].[西班牙肾脏病学会指南。腹膜透析临床实践指南]
Nefrologia. 2006;26 Suppl 4:1-184.
8
Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy--a Spanish multicentre experience.终末期肾病护理对计划开始透析及肾脏替代治疗类型的影响——一项西班牙多中心经验
Nephrol Dial Transplant. 2006 Jul;21 Suppl 2:ii51-5. doi: 10.1093/ndt/gfl191.
9
Analysis of patient flow into dialysis: role of education in choice of dialysis modality.透析患者流入情况分析:教育在透析方式选择中的作用。
Perit Dial Int. 2005 Feb;25 Suppl 3:S56-9.
10
Does predialysis nephrology care influence patient survival after initiation of dialysis?透析前肾病护理是否会影响开始透析后的患者生存率?
Kidney Int. 2005 Mar;67(3):1038-46. doi: 10.1111/j.1523-1755.2005.00168.x.

西班牙肾脏替代治疗方案的成本效益分析。

Cost-effectiveness analysis of the Spanish renal replacement therapy program.

机构信息

BAP Health Outcomes Research1 and Department of Medicine, Universidad de Oviedo, Oviedo, Spain.

出版信息

Perit Dial Int. 2012 Mar-Apr;32(2):192-9. doi: 10.3747/pdi.2011.00037. Epub 2011 Sep 30.

DOI:10.3747/pdi.2011.00037
PMID:21965620
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3525412/
Abstract

BACKGROUND

We undertook a cost-effectiveness analysis of the Spanish Renal Replacement Therapy (RRT) program for end-stage renal disease patients from a societal perspective. The current Spanish situation was compared with several hypothetical scenarios.

METHODS

A Markov chain model was used as a foundation for simulations of the Spanish RRT program in three temporal horizons (5, 10, and 15 years). The current situation (scenario 1) was compared with three different scenarios: increased proportion of overall scheduled (planned) incident patients (scenario 2); constant proportion of overall scheduled incident patients, but increased proportion of scheduled incident patients on peritoneal dialysis (PD), resulting in a lower proportion of scheduled incident patients on hemodialysis (HD) (scenario 3); and increased overall proportion of scheduled incident patients together with increased scheduled incidence of patients on PD (scenario 4).

RESULTS

The incremental cost-effectiveness ratios (ICERs) of scenarios 2, 3, and 4, when compared with scenario 1, were estimated to be, respectively, -€83 150, -€354 977, and -€235 886 per incremental quality-adjusted life year (ΔQALY), evidencing both moderate cost savings and slight effectiveness gains. The net health benefits that would accrue to society were estimated to be, respectively, 0.0045, 0.0211, and 0.0219 ΔQALYs considering a willingness-to-pay threshold of €35 000/ΔQALY.

CONCLUSIONS

Scenario 1, the current Spanish situation, was dominated by all the proposed scenarios. Interestingly, scenarios 3 and 4 showed the best results in terms of cost-effectiveness. From a cost-effectiveness perspective, an increase in the overall scheduled incidence of RRT, and particularly that of PD, should be promoted.

摘要

背景

我们从社会角度对西班牙终末期肾病患者的肾脏替代治疗(RRT)计划进行了成本效益分析。将当前西班牙的情况与几种假设情况进行了比较。

方法

使用马尔可夫链模型作为模拟西班牙 RRT 计划的基础,模拟时间跨度为 5、10 和 15 年。将当前情况(情景 1)与三种不同情景进行了比较:增加所有计划(计划)事件患者的比例(情景 2);所有计划事件患者的比例保持不变,但腹膜透析(PD)计划事件患者的比例增加,导致血液透析(HD)计划事件患者的比例降低(情景 3);以及所有计划事件患者的比例增加,加上 PD 计划事件患者的发病率增加(情景 4)。

结果

与情景 1 相比,情景 2、3 和 4 的增量成本效益比(ICER)分别估计为-€83 150、-€354 977 和-€235 886 每增加一个质量调整生命年(ΔQALY),这表明既节省了成本又略微提高了效果。如果将支付意愿阈值设定为 35 000 欧元/ΔQALY,则估计社会将分别获得 0.0045、0.0211 和 0.0219 ΔQALY 的净健康收益。

结论

情景 1,即当前西班牙的情况,被所有提议的情景所主导。有趣的是,情景 3 和 4 在成本效益方面表现最佳。从成本效益的角度来看,应促进 RRT 的总体计划发病率增加,特别是 PD 的发病率增加。